Nanoparticle augmentation of radiotherapy in sarcoma
Mené sur 179 patients adultes atteints d'un sarcome des tissus mous de stade localement avancé, cet essai de phase II-III évalue l'efficacité, du point de vue du taux de patients présentant une réponse pathologique complète, et la sécurité de la nanoparticule d'oxyde d'hafnium NBTXR3, un amplificateur de radiothérapie
Soft-tissue sarcomas represent a heterogeneous group of mesenchymal tumours that have classically been defined by their tissue of origin. In the past few years, high-throughput efforts have characterised the genomic and epigenomic landscape of these malignancies, uncovering molecular mechanisms that underlie diverse biological properties and clinical behaviours. 1However, despite this more comprehensive understanding, surgical resection remains the cornerstone of treatment for nearly all subtypes of extremity soft-tissue sarcoma. Whereas limb-sparing surgery alone has been associated with unacceptable levels of local recurrence, 2surgery plus neoadjuvant or adjuvant radiotherapy has become the dominant approach for improving local control, largely obviating the need for amputation when gross negative resection margins can be achieved. 3 With the utility of radiotherapy well established, more recent efforts have focused on augmentation strategies to achieve optimal oncological outcomes in soft-tissue sarcoma of the extremities.
The Lancet Oncology 2019